Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques. - Wikidata - wikimedia - TriplyDB

Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques.

Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques.

http://www.wikidata.org/entity/Q36496336

about

The role of infiltrating immune cells in dysfunctional adipose tissue.Athero-inflammatory nanotherapeutics: Ferulic acid-based poly(anhydride-ester) nanoparticles attenuate foam cell formation by regulating macrophage lipogenesis and reactive oxygen species generation.Nanomedicines for dysfunctional macrophage-associated diseases.Nanotherapeutics Containing Lithocholic Acid-Based Amphiphilic Scorpion-Like Macromolecules Reduce In Vitro Inflammation in Macrophages: Implications for Atherosclerosis.Editorial highlights from Cardiovascular Research.Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms.Biomedical Applications of Nanotechnology and Nanomaterials

P2860

Q38637700-C0227070-E87C-42A5-AE12-DC7DC0DE5A35 Q38682030-AC028381-21B0-47D7-B9BE-92245D9D5E68 Q39069052-4501B3A0-1190-4C67-88BB-E8A0A6E8D05E Q48114789-F28A5723-EDD6-4FC8-9D54-8F351BA0A487 Q49549470-19D3788E-CA72-4552-B1BE-621997DA2B9A Q49833824-B080B5AE-3EB3-4284-8102-32540F218F5E Q57062984-8F4C1130-88F5-4181-8569-11E3055CA6AC

P2860

Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques.

http://www.wikidata.org/entity/Q36496336

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Nanotherapeutics for inhibitio ...... on in atherosclerotic plaques.

@ast

Nanotherapeutics for inhibitio ...... on in atherosclerotic plaques.

@en

type

label

Nanotherapeutics for inhibitio ...... on in atherosclerotic plaques.

@ast

Nanotherapeutics for inhibitio ...... on in atherosclerotic plaques.

@en

prefLabel

Nanotherapeutics for inhibitio ...... on in atherosclerotic plaques.

@ast

Nanotherapeutics for inhibitio ...... on in atherosclerotic plaques.

@en

P1433

Q36496336-D0A26404-F31B-460D-8A21-A74AC5B6250E

P1476

Q36496336-A2FFCB22-9528-44BF-BBA1-F9ADAE06A8AA

P2093

Q36496336-1197B662-1A15-4EE6-9004-7769D319896C

Q36496336-79E80A31-9D3E-4890-AED0-202D97D858BA

Q36496336-8633C763-73F1-49EE-B3E6-DF717D95FBF6

Q36496336-999184DF-3EB5-42ED-AD72-AD99BF54FAED

Q36496336-B6FE652C-69B4-49D3-9AAC-FF0943C00B11

Q36496336-E7609E15-9813-40B6-BAA4-802F0DC4A32F

Q36496336-E9363DBE-35C6-49B5-B6AD-D43A161D165F

Q36496336-EB69C610-2555-4E24-8649-6A62A3FF1560

Q36496336-FDEA0546-DAA8-4814-A946-D08DD5CF38C1

P2860

Q36496336-00DFEDFC-0AF7-4B38-B29E-3BD2D82D52BC

Q36496336-0BD8A2E2-4344-4C82-AB69-C403FC8E257D

Q36496336-0C66E59D-FF2E-46D4-9FB4-F98F1A095614

Q36496336-0CDB2E2C-2F6F-4DB6-9C28-B3C356FEDBCF

Q36496336-12004A8E-EF32-4800-A4B1-4C1B3890FC29

Q36496336-129375C5-7931-4A93-BA64-69993B0D0013

Q36496336-16367A22-2A36-42AF-80FE-360487F88FEF

Q36496336-1637FF8D-8186-4C47-9323-0102086096DF

Q36496336-20729176-BB6A-4A68-AB08-41A8F0B7BAE4

Q36496336-23BC33CB-0E6C-4376-ADDF-0BC5CD8C98F9

P304

Q36496336-0E362F08-224B-492C-8C44-CD66642914A1

P31

Q36496336-C7A62338-C845-4162-9798-DA7181A42633

P356

Q36496336-65AC944C-8B20-47EA-AC12-00E42A292903

P433

Q36496336-BF270E6D-BFB7-4997-93C3-1CE39E8B0F74

P478

Q36496336-7CF99E68-D0CE-45B4-BADB-250B05D2D773

P50

Q36496336-8DD52F7C-4957-4727-9ACC-C8851AA3FB67

P577

Q36496336-F145F252-1E4D-415C-BEA9-859228E3A20D

P698

Q36496336-35B3BB70-61BA-4B57-BC67-B84AE0D40458

P921

Q36496336-0C36DC20-167B-486E-BC4B-13E1E6D6C84D

P932

Q36496336-4A2FE245-556A-427B-8831-F2BB4C4DF280

P356

P1433

Cardiovascular Research

P1476

Nanotherapeutics for inhibitio ...... on in atherosclerotic plaques.

@en

P2093

Adam W York

http://www.w3.org/2001/XMLSchema#string

Daniel R Lewis

http://www.w3.org/2001/XMLSchema#string

Hoonbyung Chae

http://www.w3.org/2001/XMLSchema#string

Latrisha K Petersen

http://www.w3.org/2001/XMLSchema#string

Laurie B Joseph

http://www.w3.org/2001/XMLSchema#string

Paul B Haser

http://www.w3.org/2001/XMLSchema#string

Prabhas V Moghe

http://www.w3.org/2001/XMLSchema#string

Saum Rahimi

http://www.w3.org/2001/XMLSchema#string

Sonali Ahuja

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice

Renal clearance of quantum dots.

Atherosclerosis — An Inflammatory Disease

Nanoparticles and inflammation

Alternative activation of macrophages

Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture

Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis.

Macrophage plasticity in experimental atherosclerosis.

Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: structure-function relationships for nanoscale amphiphilic polymers.

Amphiphilic nanoparticles repress macrophage atherogenesis: novel core/shell designs for scavenger receptor targeting and down-regulation.

P304

283-293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CVR/CVV237

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26472131

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

4724935

http://www.w3.org/2001/XMLSchema#string